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Irisin and FNDC5 in retrospect
An exercise hormone or a transmembrane receptor?
Harold P Erickson
Departments of Cell Biology and Biochemistry; Duke University Medical Center; Durham, NC USA
FNDC5 (fibronectin domain-con-taining [protein] 5) was initially 
discovered and characterized by two 
groups in 2002. In 2011 FNDC5 burst 
into prominence as the parent of irisin, 
a small protein containing the fibronec-
tin type III domain. Irisin was proposed 
to be secreted by skeletal muscle cells in 
response to exercise, and to circulate to 
fat tissue where it induced a transition 
to brown fat. Since brown fat results in 
dissipation of energy, this pathway is of 
considerable interest for metabolism and 
obesity. Here I review the original dis-
coveries of FNDC5 and the more recent 
discovery of irisin. I note in particular 
three problems in the characterization of 
irisin: the antibodies used to detect irisin 
in plasma lack validity; the recombinant 
protein used to demonstrate activity in 
cell culture was severely truncated; and 
the degree of shedding of soluble irisin 
from the cell surface has not been quan-
titated. The original discovery proposing 
that FNDC5 may be a transmembrane 
receptor may deserve a new look.
The fibronectin type 3 (FNIII) protein 
domain is one of biology’s favorite build-
ing blocks. It is found in tandem arrays 
in extracellular matrix proteins such as 
fibronectin and tenascin, and it forms 
the ligand-binding ectodomain of many 
receptors.1 FNIII domains are about 
90 amino acids (aas) long, and share only 
15–20% sequence identity. In spite of this 
limited aa sequence identity, all FNIII 
domains have an identical protein fold. 
The domain is a small globule, with 3 β 
strands on one side and 4 on the other 
(Fig. 1A). This fold is similar to that of the 
immunoglobulin domain, but one strand 
is switched to the opposite side.
Early Discoveries of FNDC5
FNDC5 (fibronectin [type 3]-domain 
containing [protein] 5) was initially dis-
covered in a genomic search, with a focus 
on FNIII domains.2 Figure 1B shows the 
aa sequence of FNDC5 with important 
features indicated. The first 29 aas of the 
mouse FNDC5 are a signal peptide, fol-
lowed immediately by the single FNIII 
domain of 94 aas. The next 28 aas are 
of unknown structure and function, and 
contain the putative cleavage site for iri-
sin (see below). This is followed by a 19 aa 
transmembrane domain and a 39 aa cyto-
plasmic domain. FNDC5 is thus a type 
I transmembrane protein with its FNIII 
domain extracellular, similar to some 
cytokine receptors.1 Based on this struc-
tural information, the authors of this ini-
tial discovery speculated that FNDC5, 
and the closely related FNDC4, “are 
likely receptors of an as yet to be identified 
ligand”.2
FNDC5 was discovered independently 
by Ferrer-Martinez et al.,3 in a search 
for peroxisomal proteins. About half of 
mammalian peroxisomal proteins are 
targeted for transport by a “conserved 
COOH-terminal tripeptide (SKL and its 
functional variants)”.4 Mouse FNDC5 has 
a C-terminal SKI. To test its localization, 
the authors expressed FNDC5 with a 
green fluorescent protein (GFP) fused 
to its N terminus, and found a punctate 
localization to peroxisomes. However, this 
fusion is probably invalid because the GFP 
would block the signal peptide, forcing 
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FNDC5 to be a cytoplasmic protein. This 
cytoplasmic protein, with its C-terminal 
SKI, should transport into peroxisomes. 
However, the native protein would be 
transported across the membrane and 
anchored as a transmembrane protein, 
eliminating any possible transport 
into peroxisomes. Moreover, FNDC5 
sequences from several vertebrate species 
have short peptide segments following 
the SKI/V/F. “Addition of even one 
aa to the C terminus of SKL kills the 
peroxisomal transport sequence” (S. 
Subramanian,4 personal communication). 
I would conclude that FNDC5 is not a 
peroxisomal protein.
The Discovery of Irisin,  
an Exercise Hormone That 
Stimulates “Browning 
of Adipocytes”
In 2012, Boström et al. rediscovered 
FNDC5 in a new context—as the pre-
cursor of “irisin”, a proposed exercise 
hormone.5 They were investigating the 
possibility that skeletal muscle, in response 
to exercise, might secrete a factor that cir-
culated in the blood stream to fat tissue, 
where it could cause the transformation 
of white or beige adipocytes into brown, 
known as the browning response. The 
potential to induce brown adipocyte tissue 
is of considerable interest for research on 
obesity, diabetes, and general metabolism. 
See Vosselman et al.6 for a recent review, 
Herzig and Wolfrum7 for an introduc-
tion to a special issue devoted to path-
ways in brown adipocyte tissue activation, 
and Raschke and Eckel8 for a review of 
myokines, signaling proteins secreted by 
muscle.
The top candidate from the screen of 
Boström et al. was FNDC5.5 They found 
that FNDC5 mRNA was upregulated 
in skeletal muscle of both mouse and 
human following exercise. They later 
used adenovirus to overexpress full length 
FNDC5 in the liver of mice. They found 
a dramatic increase in brown fat in the 
FNDC5-expressing mice (Fig. 6A of 
Boström et al.5). These two results remain 
as intriguing support for the exercise 
hormone hypothesis.
How could FNDC5, expressed as a 
transmembrane protein in skeletal muscle, 
cause an increase in brown adipocyte 
tissue? Boström et al. proposed that the 
ectodomain of FNDC5 was cleaved by 
an unknown protease, producing the 
soluble irisin protein (111 aas comprising 
the FNIII domain and a short C-terminal 
tail: spsa…tmke in Fig. 1B). Boström et 
al proposed that irisin traveled through 
the blood to fat tissue, where it interacted 
with unknown receptors to induce the 
browning response. However, I believe 
that 3 key experiments in the study of 
Boström et al. have serious flaws.
Problem 1: The Irisin 
Antibodies Are Not Valid
A key point in the study of Boström et al.5 
was to show that irisin protein was present 
in plasma of human and mouse, and that 
it was upregulated following exercise (their 
Figure 5). This was demonstrated by west-
ern blots, which used a polyclonal anti-
body obtained from the company Abcam. 
This antibody is described in the Abcam 
catalog (ab117436) as being made against 
a peptide corresponding to C-terminal 
aa 149–178 of the human FNDC5 (aa 
146–175 in mouse, magenta in Fig. 1B). 
This peptide contains primarily the trans-
membrane segment, and does not include 
any sequence from the irisin peptide. The 
Q&A section of the Abcam website has a 
Figure 1. Structure of an FnIII domain, and diagram of FnDC5 sequence showing domains. (A) a 
ribbon diagram of an FnIII domain from tenascin, from pdb file 1ten,17 generated with Pymol (http://
pymol.org/sites/default/files/pymol_0.xml). all FnIII domains have this same folding structure. 
(B) the sequence of mouse FnDC5 (nP_081678) showing domains. the FnIII domain is separated 
into proposed b strands, with the aBe sheet on the bottom and the C’CFG sheet on top.
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clear statement that “I do not expect this 
antibody to bind to the cleaved Irisin pro-
tein”. The western blots in Figures 4 and 
5 of Boström et al.5 therefore have to be 
discounted; and that means there is no 
evidence that irisin or FNDC5 protein 
actually exists in plasma.
Following the initial discovery of 
irisin,5 there have been about 20 papers 
from various groups pursuing its study. 
Many of these studies have examined 
mRNA levels of FNDC5 and other genes 
that might be related to the proposed 
exercise-hormone pathway. These assays 
of gene expression are not questioned here, 
although they have given mixed results. 
However, a number of the studies have 
also claimed to quantitate the level of irisin 
protein in plasma, as a function of exercise 
or other potential metabolic correlates. 
Regrettably these studies have all relied 
on commercially available antibodies 
or ELISA kits that have questionable 
validation. Several studies used the 
Abcam antibody to aa 149–178, which 
is irrelevant to irisin; an antibody sold by 
Acris and one from USCN Life Sciences 
are described as “FNDC5 C-term” and 
may be the same as the Abcam antibody. 
An antibody from Aviscera was listed for 
a while as “no longer available”, and is 
now removed from their catalog. None 
of these antibodies has been validated by 
quantitative western blot analysis.
An antibody and ELISA kit from 
Phoenix Pharmaceuticals, developed 
initially for immunohistology,9 seemed 
promising. However, a recent study 
by Roca-Rivada et al.10 has published 
complete (10–60 kDa) western blots 
directly comparing the antibodies from 
Abcam and Phoenix Pharmaceuticals. 
The results are not encouraging. This 
study did not look at plasma, but 
examined the proteins secreted by excised 
fat and skeletal muscle tissue. The Abcam 
antibody stained a prominent band of 
25 kDa secreted from both tissues, and a 
weak band of 50 kDa in some lanes. The 
text mentioned additional high molecular 
weight bands. The Phoenix antibody also 
stained a sharp 25 kDa band, even though 
the antigens for the Abcam and Phoenix 
antibodies do not share any sequence. The 
Phoenix antibody also stained prominent 
bands of 45–50 kDa, and in some cases 
these were much stronger than the 
25 kDa band. Unlike the original study 
of Boström et al.,5 where the stained 
bands were diffuse as expected for heavy 
glycosylation, the 25 kDa bands in Roca-
Rivada et al.10 are sharp.
Any polyclonal antiserum contains 
antibodies to cross-reacting proteins. To 
provide a quantitative measure of antigen 
levels in plasma, an antibody needs to be 
tested by quantitative western blotting for 
cross-reacting proteins in plasma, and for 
its sensitivity to the target antigen added 
to plasma. Since none of the commercial 
antibodies have been so validated, I 
suggest that all published assays of irisin 
protein levels need to be reconsidered.
Problem 2: The Recombinant 
Irisin/FNDC5 Used to 
Demonstrate Browning 
in Fat Cell Culture Was a 
Severely Truncated Protein
After identifying FNDC5 as a top myo-
kine candidate, Boström et al.5 tested a 
recombinant FNDC5 protein for activity 
in adipocyte cell culture. Their Figure 3 
shows that when cells cultured from ingui-
nal fat pads were treated with 200 ng/ml 
recombinant FNDC5 protein, there was a 
dramatic increase in Ucp1, the marker for 
brown adipocytes.
The problem is that the recombinant 
FNDC5 used in this experiment was a 
severely truncated protein. The protein 
was obtained commercially from the 
company Abnova (H00252995-P01), and 
is described in the catalog as “Human 
FNDC5 full-length ORF (NP_715637.1, 
1 aa–137 aa) recombinant protein with 
GST-tag at N-terminal”. Unfortunately, 
this protein is not full-length FNDC5, 
but is missing the first 70 aas. This 
missing segment includes the signal 
peptide and, most importantly, the first 
three β strands of the FNIII domain. 
These missing β strands, almost half of 
the FNIII domain, are colored red in 
the sequence diagramed in Figure 1B. 
(It turns out that the database entry 
NP_715637.1 missed the unusual AUA 
start codon of the human sequence, and 
chose the next methionine, 70 aas later, 
as the start. There is now an updated 
entry NP_715637.1, which contains 
the full-length protein of 212 aas.) The 
truncated protein has only the E strand 
remaining on the 3-strand side; on the 
4-strand side it is missing the C strand 
(Fig. 1A and B), so strands C' and F 
will be missing their hydrogen-bonding 
partners. One should wonder how the 
truncated protein could fold into any 
structure resembling the native FNIII 
domain, and therefore be suspicious of 
any biological activity attributed to the 
truncated FNIII peptide.
The truncation of the FNDC5 
protein used in Boström et al. has never 
been noted in the literature. However, 
in a separate study from the same group, 
the experiment was partially repeated 
with a protein that contained the full 
length FNIII domain fused at its C 
terminus to the Fc fragment of human 
immunoglobulin G.11 Figure 4C of Wu 
et al.11 shows that irisin-Fc produced a 
strong increase in Ucp1 when applied to 
cultured fat cells; however, it required a 
5-fold higher concentration to match the 
activity of the truncated Abnova FNDC5 
protein, which was tested in parallel. 
Restoring confidence in this assay will 
require extended exploration of these 
and related protein constructs to map the 
site(s) of the activity.
Problem 3: What Fraction 
of FNDC5 is Cleaved to 
Produce Soluble Irisin?
To act as a hormone, the ecto-domain of 
FNDC5 would need to be cleaved from 
its transmembrane attachment. To test for 
this Boström et al.5 used mass spectrom-
etry (MS) to analyze FNDC5 collected 
from culture medium. The MS found 
some FNDC5 in the medium, and indi-
cated that it terminated in …TMKE-140 
of the mouse sequence. Boström et al. 
concluded that an unidentified protease 
cleaved the protein at this point, releasing 
a 111 aa segment SPSAP…TMKE, which 
they named irisin. A problem with this 
experiment is that there was no quanti-
tation of shed protein relative to protein 
remaining on the cell surface. MS can be 
very sensitive, so the protein shed into the 
media might have been only a small frac-
tion of the total. It is essential to know 
what fraction of FNDC5 is cleaved, to 
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determine if cleavage and shedding is a 
major or minor pathway.
Tissues That Express FNDC5
The pattern of tissue expression was ana-
lyzed in the two original discoveries of 
FNDC5.2,3 Each group probed a com-
mercial (from Clontech) northern blot of 
adult mouse tissues, and the results were 
largely in agreement. Expression was very 
strong in heart, strong in brain, weak in 
testis and lung, and absent in spleen and 
kidney. Results were ambiguous for skel-
etal muscle, the tissue of primary inter-
est here. However, expression in skeletal 
muscle was confirmed by a more extensive 
northern analysis, which showed a fairly 
constant expression of FNDC5 mRNA in 
skeletal muscle from embryonic day 15.5 
to adult.3
A recent survey of adult human tissues 
using quantitative PCR gave a pattern 
partially confirming these early northern 
blots.12 Strong expression of FNDC5 was 
reported in skeletal muscle, pericardium, 
and rectum; moderate expression was 
found in heart, intracranial artery, tongue, 
and optic nerve. Very low expression was 
found in brain, contradicting the previous 
mouse studies.2,3 Interestingly, expression 
of FNDC5 in skeletal muscle across a range 
of human subjects was strongly correlated 
with expression of PGC1α,12 consistent 
with the proposed link of both proteins 
to exercise.5 Finally, the website BioGPS.
org shows a gene expression pattern for 
FNDC5 in adult mouse: expression was 
very high in heart, and moderately high in 
brain and skeletal muscle.
Timmons et al.13 have questioned 
whether upregulation of FNDC5 in 
skeletal muscle is actually related to 
exercise. They found, using an Affymetrix 
screen, that FNDC5 was upregulated in 
muscle following exercise only in a subset 
of elderly subjects (and they noted that 
the 8 subjects in the Boström et al. study 
were also elderly). They concluded that 
FNDC5 is likely not a primary pathway in 
the response to exercise, since the benefits 
of exercise to health apply across all ages. 
In their reply to this critique,13 Boström 
et al. noted that the earlier comprehensive 
Timmons study also failed to identify 
PGC1α as a gene upregulated by exercise, 
questioning the general validity of their 
screen.
FNDC5 Activity in Neural 
Development
The two original discoveries of FNDC5 
found that FNDC5 mRNA was highly 
expressed in adult brain.2,3 Pursuing the 
potential role in brain, the laboratory of 
Baharvand found that FNDC5 expression 
was upregulated when mouse embryonic 
stem cells were induced to differentiate 
into neurons by application of retinoic 
acid.14 They later showed that differen-
tiation of stem cells into neuroblasts was 
decreased when FNDC5 was knocked 
down by short hairpin RNA.15 In a sepa-
rate study Moon et al.16 applied full length 
recombinant irisin (not glycosylated) to 
neural cells, and observed an enhance-
ment of cell proliferation. These results 
complement the original discoveries that 
FNDC5 is highly expressed in brain.2,3
Conclusion
This leaves us with unresolved issues. 
Is irisin really an exercise hormone, 
released from skeletal muscle to act on an 
unknown receptor? Or might it actually 
remain as the ectodomain of a transmem-
brane FNDC5, perhaps a receptor with an 
unknown ligand, as suggested by Teufel 
et al.?2 This field really needs a validated 
antibody that can quantitate levels of 
FNDC5 protein in plasma and on the cell 
surface. One could then address the key 
question—is a substantial fraction of the 
ectodomain cleaved and released as a cir-
culating hormone, or does it remain in its 
tissue of origin as a transmembrane pro-
tein with an unknown function?
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